Jennerex's genetically modified smallpox vaccine shrunk tumors in liver cancer patients and extended survival by more than a year, a study shows. The company tested Pexa-Vec, the therapy treatment, on 30 individuals with advanced hepatocellular carcinoma. The 16 patients who received a high dose of Pexa-Vec lived a median of 14.1 months after injection, while the 14 who got a low dose lived a median of 6.7 months. More | Abstract